Health and Healthcare
Exelixis Slides Despite Positive Late-Stage Results
Published:
Last Updated:
Shares of Exelixis Inc. (NASDAQ: EXEL) slipped on Wednesday after the company reported results from its late-stage trial for advanced hepatocellular carcinoma (HCC). Specifically, this was a pivotal Phase 3 Celestial trial for cabozantinib. Although results were positive, investors sent shares lower.
The study showed that cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival, the trial’s primary endpoint, at the planned second interim analysis for the population of second-line and third-line patients enrolled in this study.
Median overall survival was 10.2 months with cabozantinib, compared with 8.0 months with placebo. Median progression-free survival was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo.
In this trial, 16% of patients in the cabozantinib arm and 3% of patients in the placebo arm discontinued treatment due to treatment-related adverse events.
Ghassan K. Abou-Alfa, M.D., Memorial Sloan Kettering Cancer Center, New York, and lead investigator on CELESTIAL, commented:
Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy. The clinically significant benefits in both overall survival and progression-free survival shown in the CELESTIAL trial suggest that, if approved, cabozantinib could become an important addition to the treatment landscape for these patients.
Gisela Schwab, M.D., president, Product Development and Medical Affairs, and chief medical officer, Exelixis, added:
We are excited by the potential benefit cabozantinib may offer to patients with previously treated advanced hepatocellular carcinoma. Given the worldwide prevalence of advanced hepatocellular carcinoma, there is a continued urgency to bring new treatment options to this patient population. We look forward to submitting our supplemental New Drug Application to the FDA for cabozantinib in the first quarter of 2018, and to further advancing our mission to help cancer patients recover stronger and live longer.
Shares of Exelixis traded down more than 8% at $27.12 on Wednesday, with a consensus analyst price target of $33.86 and a 52-week range of $16.72 to $32.50.
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.